Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

Name: Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Creator: Health Canada
License: https://open.canada.ca/en/open-government-licence-canada

Health Canada reviewed the potential risk of DRESS with the use of atypical antipsychotics, following the manufacturers’ voluntary update of the product safety information for Zyprexa (olanzapine) and Zeldox (ziprasidone) to include the risk of DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms). DRESS describes a group of rare but serious and potentially life-threatening side effects to medications, such as fever, severe skin rash with swollen face or peeling of the skin over large areas of the body, etc.

Publisher: Health Canada
Resources: 2
Catalogue metadata updated: 2024-05-08

Data overview

Formats: HTML
File languages: English, French

Official sources and licences

Government of Canada Open Data
Open Government Licence – Canada

Resources

Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) (French, HTML) HTML
Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) (English, HTML) HTML

Related open data

Health Canada